Xellia Pharmaceuticals signs Davos Declaration on combating antimicrobial resistance

Specialty pharmaceutical company, Xellia Pharmaceuticals has signed The Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combatting Antimicrobial Resistance (AMR).

In doing so, Xellia joins over 100 pharmaceutical, biotech, diagnostic and generic drug companies in signing the “Davos Declaration”, which was first published in January 2016.

Xellia signed the declaration, which calls for collective action against the global crisis of AMR, at the World Economic Forum Annual Meeting in Davos, Switzerland.

Carl-Åke Carlsson, CEO, Xellia said: “Antimicrobial resistance is a huge global issue and an immense challenge to overcome. As a leading supplier of specialty antibiotics, such as vancomycin and colistimethate sodium (CMS) that can often be the last-line of defence against resistant microbes, we play an important role in ensuring their responsible production and stable and reliable supply.”

“We also recognise that it is only by collaborating across countries and industries, and by taking action together that we can start to make a positive difference. As such, the signing of this Declaration validates our ongoing commitment to the manufacture of critical antibiotics and unites us with our peers in working towards the single goal of beating antimicrobial resistance, to protect patients worldwide.”

To combat the threat of AMR, Xellia, among the other attributors to the declaration, call for greater government cooperation with the industry to develop alternative market structures that provide more sustainable and predictive models for antibiotics, vaccines and diagnostics.

The declaration also regards the need for the responsible use of existing and new treatments. This is in order to help slow the rise in AMR and preserve the long-term effectiveness of existing antibiotics.